Micafungine Teva (Micafungin)

Micafungine Teva is an echinocandin antifungal that targets Candida species in serious infections.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal lesions and symptoms in immunocompromised patients.
• Candida peritonitis and intra‑abdominal infections: aids in clearing infection after abdominal surgery.
• Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in high‑risk transplant recipients.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. Disruption of cell‑wall formation leads to osmotic instability and fungal cell death, providing a fungicidal effect against susceptible Candida species.

Micafungine Teva may cause a range of adverse reactions, most of which are manageable.

Common Side Effects

• Fever: transient temperature elevation during infusion.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild to moderate pain.
• Infusion‑related reactions: erythema, flushing, or mild hypotension.
• Elevated liver enzymes: transient increase in ALT/AST.
• Rash: mild skin irritation or pruritus.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring monitoring.
• Anaphylaxis: life‑threatening allergic reaction.
• Stevens‑Johnson syndrome: severe skin and mucosal involvement.
• Renal impairment: acute kidney injury in susceptible patients.
• Neutropenia: marked reduction in white blood cells.
• Severe hypotension: marked drop in blood pressure during infusion.

Before initiating therapy, clinicians should consider several safety measures.

• Renal function monitoring: assess creatinine clearance in patients with kidney disease.
• Hepatic function monitoring: check baseline and periodic liver enzymes.
• Concomitant hepatotoxic drugs: avoid or adjust dosing when used with other liver‑affecting agents.
• Known hypersensitivity: do not administer to patients with documented allergy to micafungin or other echinocandins.
• Dose adjustment in severe hepatic impairment: consider reduced exposure and monitor closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine Teva can interact with several medications; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Co‑administration with other echinocandins: may increase toxicity without added benefit.
• Strong CYP3A4 inducers (e.g., rifampin): can markedly reduce micafungin exposure.
• Cyclosporine: concurrent use may raise micafungin plasma levels.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may increase risk of hepatotoxicity.
• Immunosuppressants (e.g., tacrolimus): monitor drug levels and liver function.
• Nephrotoxic agents (e.g., aminoglycosides): watch for additive renal impairment.